http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yoonhyeong Byun,Eun Jin Kim,Areum Lee,Young-Ah Suh,Hee Ju Sohn,Jung Min Lee,Jae Seung Kang,Yoo Jin Choi,Youngmin Han,Hongbeom Kim,Wooil Kwon,Jin-Young Jang 대한외과학회 2022 Annals of Surgical Treatment and Research(ASRT) Vol.102 No.2
Purpose: Various hemostatic agents have been introduced in therapy as postoperative bleeding is a poor prognostic factor for postoperative outcomes. These products can be divided into those that directly promote the hemostatic cascade and those that physically form a barrier by absorbing blood. The latter, powder-type hemostatic agents have the advantages of being inexpensive and more absorbable with less foreign body reactions (FBRs) and are applicable to a relatively wide area. This study was conducted to verify the safety and efficacy of a newly invented polysaccharide product (OOZFIX, Theracion Biomedical), which improves blood absorption and hemostatic effects. Methods: Two separate animal experiments were performed. The first evaluated FBRs histologically at 3 days, 2 weeks, and 4 weeks, after implantation of OOZFIX in rats, and the second compared hemostatic performance of OOZFIX and Arista AH (Bard) in the porcine liver punch biopsy model. Results: We found minimal FBRs in the 3-day group and no reactions in both the 2-week and 4-week groups after implantation of hemostatic agents. The time to hemostasis of OOZFIX was not significantly different from that of Arista AH (median [interquartile range]: 9 [6–10] minutes vs. 8 [6–10] minutes, respectively; P = 0.522). When comparing the serial bleeding grade tendency, there was no statistical difference between OOZFIX and Arista AH (P = 0.656). Conclusion: OOZFIX caused a minimal FBR that disappeared within 2 weeks in vivo, and its hemostatic performance was comparable with that of an existing agent, Arista AH. Further clinical studies are required in the future.
백혈병 세포에서 Multidrug Resistance Gene-1 (mdr1)의 과발현이 ^99m Tc-sestaMIBI 섭취에 미치는 영향
천경아,이재태,이상우,강도영,손상균,이종기,정준기,전수한,이규보 경북대학교 의학연구소 2000 경북대학교병원의학연구소논문집 Vol.4 No.1
Purpose: To determine whether 99mTc-MIBI is recognized by the multidrug resistant P-glycoprotein (Pgp), we have measured quantitatively 99mTc-MIBI uptake in cancer cells. The effects of various Pgp reversing agents on cellular 99mTc-MIBI uptake were also investigated in the presence of multidrug resistance gene-1(mdr1 gene) overexpression. Materisls and Methods: We measured percentage uptake of 99mTc-MIBI at different incubation temperatures both in mdr1 positive and negative cells. The effects of verapamil, cyclosporin, and dipyridamole on cellular uptake of 99mTc-MIBI were also evaluated with or withouts overexpression of mdr1 gene in Cultured murine leukemia L1210 cells. Results: The mdr1 gene expressing cell lines were effectively induced in in vitro with continuous application of low-dose adriamycin or vincristine. Cellular uptake of 99mTc-MIBI was higher in mdr1 negative L 1210 cells than those of mdr1 positive cells, and higher when incubated in 37℃ than 4℃. In the presence of verapamil, cyclosporin or dipyridamole, 99mTc-MIBI uptake was increased upto 604% in mdr1 positive cells. Conclusion: Cellular uptake of 99mTc-MIBI is lower in leukemia cells over-expressing mdr1 gene, and MDR-reversing agents increase cellular uptake. These results suggest that 99mTc-MIBI can be used for characterizing Pgp expression and developing MDR-reversing agents in vitro. (Korean J Nucl Med 1999;33: 152-62)
연폭로여성근로자들에서의 생물학적 연폭로 지표들의 상호관계
남택승,한구웅,김형아,김정만,이광묵 가톨릭대학 산업의학쎈타 산업의학연구소 1986 韓國의 産業醫學 Vol.25 No.3
For the purpose of obtaining of an effective biological monitoring data in terms of evaluation the health consequences of lead absorption, the female workers in the electronic industry who have been exposed to low-level lead occupationally were chosen as the subjects of our studies. We observed the 9 parameters in not only 305 lead-exposed female workers who have been exposed to lead occupationally also 254 normal female subjects who have not been exposed to lead occupationally. The parameters chosen for this study were as follows, blood lead (PbB), urine lead (PbU), δ-aminolevulinic acid in urine(ALAU), coproporphyrin in urine(CPU), zinc protoporphyrin in whole blood(ZPP), hemoglobin(Hb), hematocrit(Ht), δ-aminolevulinic acid dehydratase(ALAD) activity & ALAD activity ratio(A/R; absorbance at substrate pH 6.6/absorbance at substrate pH 5.8). The results obtained were as follows: 1. The average age of the lead-exposed female workers in the electronic industry and in the normal female subjects were 20.5±4.2 years and 21.7±3.5 years, respectively. 2. The average work duration of the lead-exposed female workers in the electronic industry was 26.4±19.4 months 3. The mean value of PbB of the lead-exposed female workers in the electronic industry and in the normal female subjects were 30.18±6.64㎍/100ml and 21.61±3.84㎍/100ml respectively. 4. In the lead-exposed female workers of the electronic industry and of the normal female subjects, the mean value of ZPP were 36.22±0.69㎍/100ml and 24.64±7.21㎍/100ml, respectively 5. In the lead-exposed female workers of the electronic industry and of the normal female subjects, the mean value of Hb were 13.98±0.57g/100ml and 14.09±0.66g/100ml, respectively. 6. The mean value of the lead-exposed female workers in the electronic industry were 55.07±17.61㎍/1 for PbU, 1.93±0.69mg/1 for ALAU, and 49.74±22.79㎍/1 for CPU, while in the normal female subjects, 44.27±15.76㎍/1 for PbU, 1.46±0.55mg/ 1 for ALAU, and 38.66±17.99㎍/1 for CPU. 7. Among various pairing of the parameters of lead exposure in the female lead-exposed workers and in the normal female subjects, the correlation between PbB and ZPP showed the highest coefficient value.
침 시술로 발생한 Non-O1, Non-O139 Vibrio cholerae에 의한 패혈증
임태섭,지아영,이중희,장수연,김인수,김영주,김범경,김승업,박준용,안상훈,한광협,김도영 Ewha Womans University School of Medicine 2013 EMJ (Ewha medical journal) Vol.36 No.S
Vibrio cholerae is mainly known to cause gastrointestinal infection after seawater exposure or raw seafood intake. It is rarely reported to cause cellulitis or sepsis, but threre has been no known case after acupuncture. Herein, We report a 56-year-old cirrhotic patient of non-O1, non-O139 Vibrio cholerae septicemia caused by cellulitis of both lower extremities after acupuncture.
( Han Ah Lee ),( Jihwan Lim ),( Seung Up Kim ),( Young-sun Lee ),( Seong Hee Kang ),( Young Kul Jung ),( Moon Young Kim ),( Ji Hoon Kim ),( Sang Gyune Kim ),( Ki Tae Suk ),( Soung Won Jung ),( Jae You 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: We investigated the performance of spleen size in predicting presence of varices in patients with compensated advanced chronic liver disease (cACLD), considering the impact of age and height in spleen size. Methods: Patients with cACLD, defined as liver stiffness (LS)≥10 kPa with transient elastography, who underwent upper gastrointestinal endoscopy and abdominal ultrasound were included. Results: A total of 1218 patients were included. Mean age was 56.0 years. Mean LS and spleen diameter were 24.2 kPa and 11.3cm, respectively. Varices were combined in 533 patients (43.8%). On multivariate analysis, older age, lower platelet count, lower albumin level, higher LS, and longer spleen diameter were significantly associated with the presence of varices (all P<0.05). On multivariate analysis for the factors associated with spleen size, younger age, taller height, alcoholic etiology, lower albumin level, higher MELD score, and higher LS were significantly associated with the longer spleen size. Using these results, formula for predictive spleen size was conducted as follows: Estimated spleen size (cm)=0.029 × height (cm) - 0.019 × age (year) + 6.670. Interestingly, estimated and measured spleen size was comparable in patients without varices (10.5cm vs. 10.4cm, P=0.134), while measured spleen size was significantly greater than estimated spleen size in patients with varices (12.4cm vs. 10.3cm, P<0.001). The ratio of measured and estimated spleen sizes (MESS ratio) were calculated as follows: MESS ratio=measured spleen size (cm)/estimated spleen size (cm). AUROC of MESS ratio for the prediction of varices was significantly higher than that of measured spleen size (0.729 vs 0.721, P=0.005). Optimal cutoff value of MESS ratio was 1.042 with sensitivity, specificity, PPV, and NPV of 73.0%, 61.0%, 59.3%, and 74.4%, respectively. Conclusions: Younger age and taller height is associated with greater spleen diameter. It should be considered in evaluating performance of spleen size in predicting varices in patients with cACLD.
( Han Ah Lee ),( Seung Woon Park ),( Sang Jung Park ),( Tae Hyung Kim ),( Sang Jun Suh ),( Young Kul Jung ),( Ji Hoon Kim ),( Hyung Joon Yim ),( Jong Eun Yeon ),( Kwan Soo Byun ),( Soon Ho Um ),( Yeon 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Definite guideline for stopping antiviral therapy for chronic hepatitisB (CHB) is not clarified yet. Previous studies suggested thatHBsAg titer is correlated with covalently closed circular DNA.Therefore, HBsAg titer might be a good indicator for off-treatment.This study was performed to determine the relationship betweenHBsAg titer and CHB relapse after off-treatment of entecavir (ETV).Methods: Patients in whom ETV was discontinued after serum HBVwith or without HBeAg clearance for more than 12 months andwho measured HBsAg titer at off-treatment were enrolled. HBV DNAreactivation was defined as increase of serum HBV DNA level >2000IU/mL, while CHB relapse was defined as HBV DNA reactivation andincrease of serum ALT level >2XULN.Results: Forty-four patients were enrolled. Age was 44.6±11.4 yearsand 28 patients (63.6%) were men. Baseline HBeAg was positive25 patients (56.8%) and serum HBV DNA level was 6.8±1.3 log10IU/mL. ETV was discontinued after 34.7±19.0 months of treatment.In HBeAg-positive CHB patients, ETV was discontinued after37.0±20.2 months of treatment, which was 31.0±19.5 and23.4±16.1 months after serum HBV DNA and HBeAg clearance,respectively. In HBeAg-negative CHB patients, ETV was discontinued after 31.6±17.4 months of treatment, which was 27.1±17.7 monthsafter serum HBV DNA clearance. HBsAg titer at off-treatment was3.0±1.0 log10 IU/mL, which was <2, 2~3, and >3 log10 IU/mL in5 (11.4%), 11 (25.0%), and 28 (63.6%) patients, respectively. Afteroff-treatment, HBV DNA reactivated in 38.7% and 66.2% and CHBwas relapsed in 4.7% and 42.3% at 6 and 12 months after off-treatment,respectively. HBsAg titer at off-treatment was significantly associatedwith HBV DNA reappearance (P=0.010) and CHB relapse(P=0.010).Conclusions: HBsAg titer at off-treatment is closely related with HBVreactivation and CHB relapse. HBsAg titer is considered as an excellentindicator of durable viral response after off-treatment.
( Han Ah Lee ),( Hyun Woong Lee ),( Jihwan Lim ),( Young-sun Lee ),( Young Kul Jung ),( Ji Hoon Kim ),( Jung Il Lee ),( Young Kul Jung ),( Hyung Joon Yim ),( Jong Eun Yeon ),( Kwan Soo Byun ),( Kwan S 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: We investigated the clinical impact of Hepatitis B core-related antigen (HBcrAg) level in defining different phases of patients with chronic hepatitis B (CHB). Methods: Stored residual serum samples from longitudinal cohorts of CHB patients in Korea University College of Medicine were studied. Patients were divided into four phases of CHB based on the histology result: hepatitis B e antigen (HBeAg)-positive chronic infection (EPI), HBeAg-positive chronic hepatitis (EPH), HBeAg-negative chronic hepatitis (ENH), HBeAg-negative chronic infection (ENI). Results: In total, 425 patients followed up for 83.1 months were included. The number of patients in each phase are as follows: 26 in EPI, 243 in EPH, 137 in ENH, and 19 in EHI. To evaluate the clinical impact of HBCrAg in differentiating EPI and EPH, patients older than 60 years old, patients with clinically or ultrasonographically evident liver cirrhosis or fibrosis-4 index (> 3.25), and HBV-DNA ≤ 20,000 IU/mL were excluded. In 145 selected patients, 26 patients were in EPI and 119 patients were in EPH. HBCrAg level was significantly higher in EPI than in EPH (8.22 log U/mL vs. 7.57 log U/mL, P=0.003). On multivariate analysis, only higher HBCrAg level (HR 0.447, P=0.013) was significantly associated with an increased probability of EPI. To evaluate the clinical impact of HBCrAg in differentiating ENH and ENI, patients with clinically or ultrasonographically evident liver cirrhosis or fibrosis-4 index (> 3.25), and HBV-DNA > 20,000 IU/mL were excluded. In 33 selected patients, 21 patients were in ENH and 12 patients were ENI. HBCrAg level was significantly higher in ENH patients than in ENI patients (5.24 log U/mL vs. 3.98 log U/mL, P<0.001). Only elevated ALT according to the KASL criteria (HR 4.875, P=0.049) was significantly associated with increased probability of ENH. Conclusions: HBcrAg level is a useful marker in differentiating EPI and EPH in patients with CHB.